查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963864

全球黏合貼片市場－產業規模、佔有率、趨勢、機會、預測：按產品類型、通路、地區和競爭格局分類，2021-2031年

Pain Patch Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球止痛貼市場預計將從 2025 年的 53.4 億美元成長到 2031 年的 70.8 億美元，複合年成長率為 4.81%。

該領域包括經皮給藥系統，旨在透過皮膚將可控鎮痛藥物直接輸送到血液中。一個關鍵的成長要素是人們越來越傾向於選擇不涉及胃腸道的非侵入性給藥方式。這最大限度地減少了通常與口服鎮痛藥相關的全身性副作用。此外，人口老化和文明病盛行率的上升，使得人們對便捷且永續的疼痛管理解決方案的需求日益迫切。根據國際疼痛研究協會預測，到2024年，全球超過20%的人口將患有慢性疼痛，這意味著龐大的患者群體亟需有效且長期的治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 53.4億美元
市場規模：2031年 70.8億美元
複合年成長率：2026-2031年 4.81%
成長最快的細分市場 非鴉片類貼劑
最大的市場 北美洲

儘管市場需求強勁，但由於經皮給藥系統法規結構嚴格，市場仍面臨許多障礙。製造商必須經過複雜的核准程序，證明黏合劑的安全性以及藥物吸收的長期穩定性。這些嚴格的合規標準往往導致產品開發週期延長和成本增加，嚴重阻礙了市場快速成長和新配方的上市。

市場促進因素

隨著醫療機構優先考慮更安全的口服麻醉劑替代方案，向非鴉片類和非成癮性疼痛治療​​的轉變正在加速，從根本上重塑了全球止痛貼市場。這項轉變主要源自於持續不斷的鴉片類藥物濫用公共衛生危機，促使臨床醫生和監管機構實施以經皮治療方法為重點的多面向疼痛管理策略。這些措施的成功在近期發布的國家數據中得到了印證。根據美國疾病管制與預防中心 (CDC) 於 2025 年 2 月發布的《藥物過量死亡初步報告》，截至 2024 年 9 月的 12 個月的初步以金額為準顯示，藥物過量死亡人數下降了約 24%。這一顯著下降凸顯了整個產業向非全身性解決方案的轉變。例如，雙氯芬酸鈉和Lidocaine貼片可在局部緩解疼痛，而不會像傳統鴉片類藥物那樣帶來呼吸抑制和成癮等嚴重風險。

同時，經皮給藥系統的技術進步正透過提高患者用藥便利性和藥物滲透性來推動市場擴張。控制釋放膜和黏附技術的創新增強了藥物的持續釋放，直接促進了領先生產商的商業性成功。例如，久光製藥株式會社在其2025年4月發布的「截至2025年2月的會計年度合併會計報告」中披露，其銷售額同比成長10.1%，這主要歸功於其旗艦經皮製劑的強勁表現。此外，監管機構也積極支持這些創新。根據《貝克爾醫院評論》2025年12月報道，美國食品藥品監督管理局（FDA）當年核准了73種首次學名藥，其中包括一種用於治療帶狀皰疹後遺症神經痛的新型Lidocaine貼劑，從而擴大了重要經皮療法的可及性。

市場挑戰

嚴格的經皮給藥系統監管架構是全球止痛貼市場擴張的主要障礙。製造商必須遵守複雜的核准流程，以檢驗黏合劑成分的安全性並確保藥物長期穩定吸收。這些嚴格的合規要求需要進行全面的臨床試驗和精細的配方改進，直接導致產品開發週期延長和營運成本增加。因此，這些高准入門檻限制了新產品的推出頻率，並阻礙了潛在的市場進入者，從而減緩了整體市場成長。

繁重的監管負擔造成了資金和時間上的雙重壓力，令許多公司難以承受。根據美國製藥商協會（PhRMA）預測，到2024年，一種新藥的平均研發週期將長達10至15年，需要約26億美元的投資。如此龐大的資源需求凸顯了將創新經皮鎮痛方案推向商業化的複雜性，也有效阻礙了製藥業快速回應患者日益成長的需求。

市場趨勢

天然、草本和含CBD產品的日益普及正在顯著影響市場格局。隨著消費者越來越尋求替代傳統藥物的整體療法，這一趨勢推動了對含有樟腦、薄荷醇和麻提取物等植物來源鎮痛成分的非處方經皮貼劑的需求。與合成鴉片類藥物相比，這些產品被認為更安全，適合長期使用。消費者偏好的這種轉變也體現在消費者對知名天然療法的數位參與度不斷提高。根據2024年3月發布的《久光製藥美國公司：90年來在疼痛緩解領域的開拓》報告，該公司旗艦貼片品牌的搜尋量在2023年飆升了98.8%。這項數據凸顯了大眾對便捷易得、處方箋的天然貼片療法在日常疼痛緩解方面的強烈需求。

同時，非藥物療法領域也在取得進展，智慧互聯的穿戴式止痛貼片應運而生。這些先進系統利用生物電子學和奈米技術，透過皮膚調節疼痛訊號，為擔心副作用和藥物交互作用的患者提供無藥物的替代方案。越來越多的同行評審研究支持這些創新技術的臨床可行性。根據美國國立衛生研究院 (NIH) 於 2024 年 4 月發表的綜述文章《奈米技術在疼痛管理中的應用》，使用新型奈米電容器貼片的患者術後疼痛較標準治療降低了 34%。這種電子調節技術的整合標誌著疼痛緩解領域向個人化、數位化解決方案邁出了變革性的一步。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球黏合貼片市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（非鴉片類貼片、鴉片類貼片）
    • 依類型（處方藥、非處方藥）
    • 分銷管道（醫院藥房、藥局/零售藥房、線上供應商）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美黏合補片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲黏合貼片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區黏合貼片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲黏合貼片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲黏合貼片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球黏合貼片市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • NEXGEL Inc.
  • Viatris Inc.
  • Johnson and Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sorrento Therapeutics Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo, Inc.
  • Purdue Pharma LP
  • Amneal Pharmaceuticals LLC
  • GrUnenthal GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18840

The Global Pain Patch Market is projected to expand from a valuation of USD 5.34 billion in 2025 to USD 7.08 billion by 2031, reflecting a compound annual growth rate of 4.81%. This sector comprises transdermal therapeutic systems engineered to administer controlled analgesic medication directly into the bloodstream through the skin. Key growth factors include a growing preference for noninvasive delivery methods that avoid the gastrointestinal tract, thereby minimizing systemic side effects typically linked to oral painkillers. Furthermore, the rising geriatric population and the increasing incidence of lifestyle-related conditions create a strong need for convenient, sustained pain management options. According to the International Association for the Study of Pain, over 20% of the world's population suffered from chronic pain in 2024, highlighting the vast patient base requiring effective, long-term therapeutic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.34 Billion
Market Size 2031USD 7.08 Billion
CAGR 2026-20314.81%
Fastest Growing SegmentNon-Opioid Patches
Largest MarketNorth America

Despite strong demand, the market encounters substantial hurdles due to the strict regulatory frameworks overseeing transdermal drug delivery systems. Manufacturers face intricate approval procedures to prove the safety of adhesive materials and the consistent efficacy of drug absorption over time. These rigorous compliance standards frequently lead to prolonged product development cycles and elevated costs, acting as significant barriers to rapid market growth and the launch of new formulations.

Market Driver

The Global Pain Patch Market is being fundamentally reshaped by an accelerated transition toward non-opioid and non-addictive pain treatments, as healthcare providers prioritize safer alternatives to oral narcotics. This shift is largely propelled by the ongoing public health crisis regarding opioid abuse, prompting clinicians and regulatory bodies to implement multimodal pain management strategies that highlight transdermal options. The success of these measures is evident in recent national data; according to the Centers for Disease Control and Prevention's 'Provisional Drug Overdose Death Counts' report from February 2025, provisional figures indicated a nearly 24% decrease in drug overdose deaths for the 12-month period ending in September 2024. This notable decline emphasizes the industry-wide move toward non-systemic solutions, such as diclofenac and lidocaine patches, which provide localized relief without the severe risks of respiratory depression and dependency linked to traditional opioids.

Concurrently, technological progress in transdermal drug delivery systems is driving market expansion by improving patient convenience and drug permeation. Innovations in rate-controlling membranes and adhesive technologies have enhanced the sustained release of medication, directly bolstering the commercial success of major manufacturers. For example, Hisamitsu Pharmaceutical reported in its April 2025 'Consolidated Financial Results for the Fiscal Year Ended February 28, 2025' that net sales rose by 10.1% year-on-year, a growth attributed largely to the strong performance of its flagship transdermal products. Additionally, regulatory agencies are actively backing this innovation; according to Becker's Hospital Review in December 2025, the FDA approved 73 first-time generic drugs during the year, including a new lidocaine patch formulation for post-herpetic neuralgia, thereby widening access to critical transdermal therapies.

Market Challenge

The stringent regulatory frameworks that govern transdermal drug delivery systems represent a major obstacle to the expansion of the Global Pain Patch Market. Manufacturers are obligated to navigate intricate approval pathways to validate the safety of adhesive ingredients and guarantee consistent drug absorption efficacy over extended durations. These exacting compliance requirements demand comprehensive clinical trials and meticulous formulation refinements, which directly result in prolonged product development schedules and increased operational expenses. As a result, these high entry barriers restrict the frequency of new product introductions and discourage potential market entrants, thereby retarding overall market growth.

This heavy regulatory burden establishes a financial and temporal landscape that is challenging for many enterprises to maintain. According to the Pharmaceutical Research and Manufacturers of America, the average development timeline for a new pharmaceutical product in 2024 ranged from 10 to 15 years, requiring an investment of roughly $2.6 billion. This significant resource demand highlights the complexity of bringing innovative transdermal pain management solutions to the commercial stage, effectively hindering the industry's capacity to swiftly respond to rising patient needs.

Market Trends

The market is being significantly shaped by the increasing popularity of natural, herbal, and CBD-infused products, as consumers increasingly search for holistic alternatives to standard pharmaceuticals. This trend is fueling demand for over-the-counter transdermal systems containing plant-based analgesics such as camphor, menthol, and hemp extracts, which are viewed as safer for long-term application compared to synthetic opioids. This shift in consumer preference is reflected in the rising digital engagement with well-known natural formulations. According to the 'Hisamitsu America Marks 90 Years of Pioneering Pain Relief' report from March 2024, search interest for the company's primary patch brand surged by 98.8% in 2023. This data point underscores the strong public intention to use accessible, non-prescription natural patch therapies for daily pain relief.

At the same time, the sector is experiencing a non-pharmacological evolution with the advent of smart and connected wearable pain patches. These sophisticated systems utilize bio-electronics and nanotechnology to modulate pain signals through the skin, providing a drug-free alternative for patients concerned about side effects or chemical interactions. The clinical feasibility of these innovations is increasingly bolstered by peer-reviewed studies. According to an April 2024 review by the National Institutes of Health titled 'Nanotechnology for Pain Management,' patients using a novel nanocapacitor-based patch reported a 34% decrease in postoperative pain relative to the standard of care. This incorporation of electronic modulation signifies a transformative advance toward personalized, digital-first solutions for pain relief.

Key Market Players

  • NEXGEL Inc.
  • Viatris Inc.
  • Johnson and Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sorrento Therapeutics Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo, Inc.
  • Purdue Pharma L.P.
  • Amneal Pharmaceuticals LLC
  • GrUnenthal GmbH

Report Scope

In this report, the Global Pain Patch Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pain Patch Market, By Product Type

  • Non-Opioid Patches
  • Opioid Patches

Pain Patch Market, By Type

  • Prescription Medicines
  • OTC Medicines

Pain Patch Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

Pain Patch Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pain Patch Market.

Available Customizations:

Global Pain Patch Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pain Patch Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Non-Opioid Patches, Opioid Patches)
    • 5.2.2. By Type (Prescription Medicines, OTC Medicines)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pain Patch Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pain Patch Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Pain Patch Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Pain Patch Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Pain Patch Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pain Patch Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Pain Patch Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Pain Patch Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Pain Patch Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Pain Patch Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Pain Patch Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pain Patch Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Pain Patch Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Pain Patch Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Pain Patch Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Pain Patch Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Pain Patch Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pain Patch Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Pain Patch Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Pain Patch Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Pain Patch Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pain Patch Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Pain Patch Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Pain Patch Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pain Patch Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NEXGEL Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Viatris Inc.
  • 15.3. Johnson and Johnson
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Sorrento Therapeutics Inc.
  • 15.6. Hisamitsu Pharmaceutical Co., Inc.
  • 15.7. Endo, Inc.
  • 15.8. Purdue Pharma L.P.
  • 15.9. Amneal Pharmaceuticals LLC
  • 15.10. GrUnenthal GmbH

16. Strategic Recommendations

17. About Us & Disclaimer